• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
WANG Shaojie, LI Xiaojie, XU Zhimeng, YAN Kang, CHEN Xi, JIANG Zhenzhou, ZHANG Luyong. Improvement of emodin on acute fatty liver in mice[J]. Journal of China Pharmaceutical University, 2017, 48(1): 89-95. DOI: 10.11665/j.issn.1000-5048.20170114
Citation: WANG Shaojie, LI Xiaojie, XU Zhimeng, YAN Kang, CHEN Xi, JIANG Zhenzhou, ZHANG Luyong. Improvement of emodin on acute fatty liver in mice[J]. Journal of China Pharmaceutical University, 2017, 48(1): 89-95. DOI: 10.11665/j.issn.1000-5048.20170114

Improvement of emodin on acute fatty liver in mice

More Information
  • To observe the effects of emodin(Emo)on acute fatty liver in mice induced by DL-ethionine(DL-Eth)or tetracyclin(Tetra)and its potential mechanism, ICR mice of acute fatty liver model induced by DL-Eth were orally administered with Emo or positive control, ursodeoxycholic acid(UDCA)for 7 days. On day 7, except that the control and Emo groups were treated with vehicle control, animals were orally administered with DL-Eth to induce acute fatty liver model. ICR mice of acute fatty liver model induced by Tetra were orally administered with Emo or positive control, Dong Bao Gan Tai (DB)or total flavonoid C-glycosides from Abrus mollis extract(AME)for 7 days. From day 4, except that the control group was treated with vehicle control, animals were injected with Tetra intraperitoneally for 4 days to induce acute fatty liver model. Liver histopathological analyses were determined by HE staining. Serum aspartate transaminase(AST), alanine transaminase(ALT), serum triglyceride(TG), hepatic TG and hepatic total cholesteol(TC)were detected. The expression of phosphorylated AMP-activated kinase(p-AMPK), phosphorylated acetyl-CoA carboxylase(p-ACC), SREBP1 and fatty acid synthase(FAS)were determined by Western blot. The expression of fatty acid translocase(CD36), peroxisome proliferator activated receptor alpha(PPARα)and microsomal triglyceride transfer protein(MTTP)in liver were determined by RT-PCR. Compared with model groups, Emo could improve hepatocyte swelling and hepatic steatosis induced by DL-Eth or Tetra. Serum AST, ALT, serum TG, hepatic TG and hepatic TC were decreased by Emo significantly. DL-Eth-induced increase of fatty acid synthetase-associated protein was down-regulated by Emo. Fatty acid uptake was down-regulated by Emo; fatty acid oxidation and secretion were increased by Emo. Emo might be effective in preventing acute fatty liver in mice induced by DL-Eth or Tetra.
  • [1]
    Hardwick JP,Osei-Hyiaman D,Wiland H,et al.PPAR/RXR regulation of fatty acid metabolism and fatty acid omega-hydroxylase(CYP4)isozymes:implications for prevention of lipotoxicity in fatty liver disease[J].PPAR Res,2009,2009:952734.
    [2]
    Portincasa P, Grattagliano I, Palmieri VO, et al. Nonalcoholic steatohepatitis:recent advances from experimental models to clinical management[J].Clin Biochem,2005,38(3):203-217.
    [3]
    Xue J,Ding W,Liu Y.Anti-diabetic effects of emodin involved in the activation of PPARgamma on high-fat diet-fed and low dose of streptozotocin-induced diabetic mice[J].Fitoterapia,2010,81(3):173-177.
    [4]
    Song P,Kim JH,Ghim J,et al.Emodin regulates glucose utilization by activating AMP-activated protein kinase[J].J Biol Chem,2013,288(8):5732-5742.
    [5]
    Heo SK, Yun HJ, Park WH, et al. Emodin inhibits TNF-alpha-induced human aortic smooth-muscle cell proliferation via caspase-and mitochondrial-dependent apoptosis[J].J Cell Biochem,2008,105(1):70-80.
    [6]
    Wang CH, Gao ZQ, Ye B, et al. Effect of emodin on pancreatic fibrosis in rats[J].World J Gastroenterol,2007,13(3):378-382.
    [7]
    Liu WH,Qi Y,Jia D.Research progress on experimental models of non-alcoholic fatty liver disease[J].Shanghai J Tradit Chin Med(上海中医药杂志),2015,49(3):95-97.
    [8]
    Yoshizawa F,Mochizuki S,Doi M,et al.Ethionine-induced ATP depletion represses mTOR signaling in the absence of increases in AMP-activated protein kinase activity in the rat liver[J].Biosci Biotechnol Biochem,2009,73(9):1984-1988.
    [9]
    Yu HY,Wang BL,Zhao J,et al.Protective effect of bicyclol on tetracycline-induced fatty liver in mice[J].Toxicology,2009,261(3):112-118.
    [10]
    Choi YJ, Lee CH, Lee KY, et al. Increased hepatic Fatty Acid uptake and esterification contribute to tetracycline-induced steatosis in mice[J].Toxicol Sci,2015,145(2):273-282.
    [11]
    BénichouC.Criteria of drug-induced liver disorders.Report of an international consensus meeting[J].J Hepatol,1990,11(2):272-276.
    [12]
    Kohjima M,Enjoji M,Higuchi N,et al.Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease[J].Int J Mol Med,2007,20(3):351-358.
    [13]
    Raghow R,Yellaturu C,Deng X,et al.SREBPs:the crossroads of physiological and pathological lipid homeostasis[J].Trends Endocrinol Metab,2008,19(2):65-73.
    [14]
    Browning JD,Horton JD.Molecular mediators of hepatic steatosis and liver injury[J].J Clin Invest,2004,114(2):147-152.
    [15]
    Li Y, Xu S, Mihaylova MM, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice[J].Cell Metab,2011,13(4):376-388.
  • Related Articles

    [1]WANG Songkai, ZOU Yuchen, SUN Shipeng, YAN Zhiye, TANG Weiwei, LI Ping, LI Bin. Recent advances in mass spectrometry imaging and its application in drug research[J]. Journal of China Pharmaceutical University, 2023, 54(6): 653-661. DOI: 10.11665/j.issn.1000-5048.2023091901
    [2]FENG Yang, XU Xiao, MO Ran. Advances in lymphatic targeted drug delivery system for treatment of tumor metastasis[J]. Journal of China Pharmaceutical University, 2020, 51(4): 425-432. DOI: 10.11665/j.issn.1000-5048.20200406
    [3]ZHOU Yeshu, WANG Yanmei, ZHANG Beiyuan, WU Shuaicong, YANG Lei, YIN Lifang. Research progress of inorganic nanomaterials in drug delivery system[J]. Journal of China Pharmaceutical University, 2020, 51(4): 394-405. DOI: 10.11665/j.issn.1000-5048.20200403
    [4]WEI Yuanyuan, YANG Fan, TANG Jie, YU Lifang. Advances in the research of anti-tuberculosis drugs[J]. Journal of China Pharmaceutical University, 2020, 51(2): 231-239. DOI: 10.11665/j.issn.1000-5048.20200215
    [5]HAN Xiu, QI Xiaole, WU Zhenghong. Advances in self-assemblied DNA nanocages as drug delivery systems[J]. Journal of China Pharmaceutical University, 2017, 48(6): 663-669. DOI: 10.11665/j.issn.1000-5048.20170605
    [6]CHEN Xing, KANG Yang, WU Jun. Advances in biodegradable functional polymers based protein drug delivery system[J]. Journal of China Pharmaceutical University, 2017, 48(2): 142-149. DOI: 10.11665/j.issn.1000-5048.20170203
    [7]JIANG Lu, CHEN Dandan, SUN Minjie, PING Qineng, ZHANG Can. Advances of wax matrix tablets[J]. Journal of China Pharmaceutical University, 2016, 47(4): 497-502. DOI: 10.11665/j.issn.1000-5048.20160418
    [8]YAO Guilin, WANG Haiyong, LU Tao. Advances of the uricosuric drugs[J]. Journal of China Pharmaceutical University, 2016, 47(4): 491-496. DOI: 10.11665/j.issn.1000-5048.20160417
    [9]LIU Yanhong, ZHOU Jianping, HUO Meirong. Advances in the tumor microenvironment-responsive smart drug delivery nanosystem[J]. Journal of China Pharmaceutical University, 2016, 47(2): 125-133. DOI: 10.11665/j.issn.1000-5048.20160201
    [10]WANG Ruoning, LIU Congyan, ZHOU Jianping, CHEN Jian, WANG Wei. Advances in the research of lipoprotein-based nano scale drug delivery systems[J]. Journal of China Pharmaceutical University, 2014, 45(1): 10-16. DOI: 10.11665/j.issn.1000-5048.20140102

Catalog

    Article views PDF downloads Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return